RA
ALXN

Rational Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Rational Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12
Closed -$1K – 640
2020
Q3 		$1K Sell
12
-140
-92% -$15.1K ﹤0.01% 585
2020
Q2 		$17K Buy
+152
New +$16.1K 0.01% 303
2020
Q1 		– Sell
-1,125
Closed -$122K – 555
2019
Q4 		$122K Buy
1,125
+944
+522% +$101K 0.06% 262
2019
Q3 		$18K Buy
181
+153
+546% +$17.2K 0.01% 466
2019
Q2 		$4K Sell
28
-15,338
-100% -$1.98M ﹤0.01% 530
2019
Q1 		$2.08M Buy
15,366
+15,327
+39,300% +$1.91M 0.56% 66
2018
Q4 		$4K Sell
39
-15
-28% -$1.77K ﹤0.01% 445
2018
Q3 		$8K Buy
+54
New +$6.77K ﹤0.01% 409
2015
Q3 		$6K Hold
41
– – ﹤0.01% 394
2015
Q2 		$7K Sell
41
-792
-95% -$137K ﹤0.01% 398
2015
Q1 		$144K Sell
833
-321
-28% -$58.1K 0.03% 204
2014
Q4 		$214K Buy
+1,154
New +$214K 0.04% 215
2013
Q4 		$469K Buy
3,529
+3,432
+3,538% +$412K 0.04% 351
2013
Q3 		$11K Hold
97
– – ﹤0.01% 824
2013
Q2 		$9K Buy
+97
New +$9.35K ﹤0.01% 845

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Rational Advisors's ALXN Position: Q4 2020 in Review

Rational Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 12 shares — an estimated $1K sold.

Rational Advisors first reported a position in ALXN in Q2 2013 and held it in 15 quarters. The position peaked at $2.08M in Q1 2019. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Rational Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Rational Advisors sold 12 Alexion Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Rational Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Rational Advisors's Alexion Pharmaceuticals position peaked at $2.08M in Q1 2019.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Rational Advisors's 13F filing for Q4 2020, filed 5 Feb 2021.